Intergalactic Therapeutics

Investors

Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

Investors & News

Investors

News

CGTLive – ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Studies

BioPharma-Reporter – Intergalactic plans to progress non-viral gene therapy program into the clinic

Ophthalmology Times – Intergalactic Therapeutics announces positive preclinical results of its platform in ABCA4 retinopathies

Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies

Labiotech.eu – 5 female-led biotech startups making waves

Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer

BioSpace – Top Life Sciences Startups to Watch in 2023

Intergalactic Therapeutics Announces Scientific Advisory Board Membership

ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding